End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.54 CNY | -1.49% | -2.55% | -10.23% |
10-25 | Changchun BCHT Biotechnology Co. Reports Earnings Results for the Nine Months Ended September 30, 2024 | CI |
08-16 | Changchun BCHT Biotechnology H1 Profit Up 24%, Operating Income Rises 11% | MT |
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | 11.77 | 14.57 | 4.51 | 2.36 | 7.26 | |
Return on Total Capital | 16.03 | 19.95 | 5.76 | 2.87 | 8.91 | |
Return On Equity % | 24.39 | 29.95 | 9.37 | 5.2 | 13.22 | |
Return on Common Equity | 24.39 | 29.95 | 9.37 | 5.2 | 13.22 | |
Margin Analysis | ||||||
Gross Profit Margin % | 89.47 | 87.77 | 80.99 | 83.02 | 88.47 | |
SG&A Margin | 53.67 | 47.84 | 46.25 | 51.59 | 43.89 | |
EBITDA Margin % | 33.27 | 36.84 | 25.6 | 21.55 | 34.74 | |
EBITA Margin % | 29.29 | 34 | 22.02 | 17.35 | 31.84 | |
EBIT Margin % | 28.89 | 32.76 | 19.92 | 14.93 | 29.7 | |
Income From Continuing Operations Margin % | 22.65 | 29.02 | 20.26 | 16.94 | 27.46 | |
Net Income Margin % | 22.65 | 29.02 | 20.26 | 16.94 | 27.46 | |
Net Avail. For Common Margin % | 22.65 | 29.02 | 20.26 | 16.94 | 27.46 | |
Normalized Net Income Margin | 17.55 | 20.6 | 13.03 | 10.52 | 19 | |
Levered Free Cash Flow Margin | 8.51 | -12.34 | -38.93 | -27.8 | -18.33 | |
Unlevered Free Cash Flow Margin | 9.04 | -12.16 | -38.91 | -27.8 | -18.3 | |
Asset Turnover | ||||||
Asset Turnover | 0.65 | 0.71 | 0.36 | 0.25 | 0.39 | |
Fixed Assets Turnover | 1.62 | 2.06 | 1.08 | 0.7 | 0.98 | |
Receivables Turnover (Average Receivables) | 3.21 | 2.71 | 1.6 | 1.24 | 1.44 | |
Inventory Turnover (Average Inventory) | 1.11 | 1.52 | 1.18 | 0.84 | 1.08 | |
Short Term Liquidity | ||||||
Current Ratio | 1.26 | 1.8 | 2.93 | 2.87 | 2.21 | |
Quick Ratio | 1.08 | 1.53 | 2.56 | 2.56 | 1.98 | |
Operating Cash Flow to Current Liabilities | 0.41 | 0.31 | 0.19 | 0.06 | 0.25 | |
Days Sales Outstanding (Average Receivables) | 113.61 | 135.21 | 227.44 | 295.08 | 253.63 | |
Days Outstanding Inventory (Average Inventory) | 329.33 | 241.54 | 309.43 | 434.81 | 339.34 | |
Average Days Payable Outstanding | 97.66 | 39.2 | 55.2 | 122 | 35.52 | |
Cash Conversion Cycle (Average Days) | 345.27 | 337.55 | 481.67 | 607.89 | 557.44 | |
Long Term Solvency | ||||||
Total Debt/Equity | 16.29 | - | - | - | 0.51 | |
Total Debt / Total Capital | 14.01 | - | - | - | 0.51 | |
Total Liabilities / Total Assets | 36.02 | 27.86 | 18.13 | 16.9 | 20.33 | |
EBIT / Interest Expense | 33.96 | 116.59 | 728.25 | - | 768.77 | |
EBITDA / Interest Expense | 39.11 | 131.13 | 936.1 | - | 899.25 | |
(EBITDA - Capex) / Interest Expense | 23.64 | 48.22 | -988.88 | - | 231.61 | |
Total Debt / EBITDA | 0.51 | - | - | - | 0.03 | |
Net Debt / EBITDA | -0.33 | -0.58 | -3.75 | -3.75 | -0.67 | |
Total Debt / (EBITDA - Capex) | 0.84 | - | - | - | 0.13 | |
Net Debt / (EBITDA - Capex) | -0.55 | -1.59 | 3.55 | 14.48 | -2.58 | |
Growth Over Prior Year | ||||||
Total Revenues, 1 Yr. Growth % | -4.24 | 47.73 | -16.6 | -10.86 | 70.3 | |
Gross Profit, 1 Yr. Growth % | -3.02 | 44.92 | -23.05 | -8.62 | 81.48 | |
EBITDA, 1 Yr. Growth % | 73.39 | 63.6 | -42.04 | -24.98 | 174.59 | |
EBITA, 1 Yr. Growth % | 82.31 | 71.49 | -45.99 | -29.76 | 212.43 | |
EBIT, 1 Yr. Growth % | 81.36 | 67.54 | -49.29 | -33.2 | 238.87 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 72.6 | 89.23 | -41.77 | -25.46 | 175.98 | |
Net Income, 1 Yr. Growth % | 72.6 | 89.23 | -41.77 | -25.46 | 175.98 | |
Normalized Net Income, 1 Yr. Growth % | 88.22 | 73.37 | -47.26 | -27.73 | 207.66 | |
Diluted EPS Before Extra, 1 Yr. Growth % | 69.44 | 86.89 | -45.61 | -29.03 | 175 | |
Accounts Receivable, 1 Yr. Growth % | 19.91 | 121.68 | 4.2 | 26.77 | 61.84 | |
Inventory, 1 Yr. Growth % | -12.59 | 69.06 | 65.08 | -20.4 | 3.6 | |
Net Property, Plant and Equip., 1 Yr. Growth % | 5.74 | 26.75 | 83.71 | 14.13 | 27 | |
Total Assets, 1 Yr. Growth % | 12.27 | 55.84 | 69.18 | 2.61 | 17.8 | |
Tangible Book Value, 1 Yr. Growth % | 24.65 | 63.21 | 108.56 | 5.06 | 9.46 | |
Common Equity, 1 Yr. Growth % | 26.7 | 75.7 | 92 | 4.15 | 12.95 | |
Cash From Operations, 1 Yr. Growth % | -13.71 | -10.15 | -32.92 | -71.62 | 540.93 | |
Capital Expenditures, 1 Yr. Growth % | -29.12 | 161.5 | 88.5 | -54.06 | 61.89 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | -314.17 | 163.03 | -36.34 | 12.28 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | -298.71 | 166.71 | -36.31 | 12.13 | |
Dividend Per Share, 1 Yr. Growth % | - | - | - | 50 | 0 | |
Compound Annual Growth Rate Over Two Years | ||||||
Total Revenues, 2 Yr. CAGR % | - | 18.94 | 11 | -13.78 | 23.21 | |
Gross Profit, 2 Yr. CAGR % | - | 18.55 | 5.6 | -16.15 | 28.78 | |
EBITDA, 2 Yr. CAGR % | - | 68.43 | -2.63 | -34.06 | 43.52 | |
EBITA, 2 Yr. CAGR % | - | 76.82 | -3.76 | -38.41 | 48.14 | |
EBIT, 2 Yr. CAGR % | - | 74.31 | -7.83 | -41.8 | 50.45 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 80.72 | 4.97 | -34.12 | 43.43 | |
Net Income, 2 Yr. CAGR % | - | 80.72 | 4.97 | -34.12 | 43.43 | |
Normalized Net Income, 2 Yr. CAGR % | - | 80.64 | -4.38 | -38.39 | 49.11 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | 77.95 | 0.82 | -37.87 | 39.7 | |
Accounts Receivable, 2 Yr. CAGR % | - | 63.04 | 51.98 | 14.93 | 43.23 | |
Inventory, 2 Yr. CAGR % | - | 21.57 | 67.06 | 14.63 | -9.19 | |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 15.77 | 52.6 | 44.8 | 20.4 | |
Total Assets, 2 Yr. CAGR % | - | 32.27 | 62.38 | 31.76 | 9.94 | |
Tangible Book Value, 2 Yr. CAGR % | - | 42.63 | 84.5 | 48.03 | 7.24 | |
Common Equity, 2 Yr. CAGR % | - | 49.2 | 83.67 | 41.41 | 8.46 | |
Cash From Operations, 2 Yr. CAGR % | - | -11.95 | -22.37 | -56.37 | 34.87 | |
Capital Expenditures, 2 Yr. CAGR % | - | 36.14 | 122.02 |